Ahead Therapeutics SL is the result of a joint research project with a strong nano component between the Germans Trias i Pujol Research Institute (IGTP), the ICN2 and ICREA. It was created to advance the development of therapies for autoimmune diseases and pursue their application in a clinical setting. Just a few months in, the new company has already attracted 1.1 million euros in private investment.